Lyn Dawson
Acute Care · Rio Rancho, NMNPI 1568643146
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Nevro Corp. accounts for 64.1% of it on its own, with 4 other manufacturers making up the rest.
Across 52 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$869
- Globus Medical$330
- Medtronic$90
- Masimo Corporation$43
- Boston Scientific$24
What the payments were for
- Food & beverage$1,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 38 | $869 |
| Globus Medical | 10 | $330 |
| Medtronic | 2 | $90 |
| Masimo Corporation | 1 | $43 |
| Boston Scientific | 1 | $24 |
How this compares
$1,355 in reported general payments places this provider in the 80th percentile of 132 acute care providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LyricaPregabalin | 19 | $14,282 |
| Oxycodone Hcl | 596 | $13,028 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 71 | $12,684 |
| Xtampza ErOxycodone Myristate | 20 | $11,889 |
| LinzessLinaclotide | 21 | $11,111 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 238 | $9,883 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 396 | $9,028 |
| Naloxone Hcl | 53 | $3,765 |
| Gabapentin | 218 | $3,316 |
| Pregabalin | 167 | $3,309 |
| Duloxetine Hcl | 79 | $2,876 |
| Tramadol Hcl | 206 | $2,335 |
| Morphine Sulfate ErMorphine Sulfate | 98 | $2,219 |
| Baclofen | 131 | $2,096 |
| Tizanidine Hcl | 119 | $1,459 |
Paid to pharmacies, not to this prescriber.
Other acute care in Rio Rancho
- Taryn DenezpiAlbuquerque$11K
- Sara WhiteSanta Fe$11K
- Catherine MahoneyAlbuquerque$10K
- Samantha MatteucciAlbuquerque$8K
- Bernadette HerreraLas Cruces$6K
- Isabel TorresAlbuquerque$5K
- Susann RavessoudLas Cruces$5K
- Kalina CordovaAlbuquerque$4K
- Viridiana ArellanoLas Cruces$3K
- Marissa PettitAlbuquerque$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.